Treatment of life-threatening type I refractory coeliac disease with long-term infliximab

G. Costantino, A. della Torre, M. A. Lo Presti, R. Caruso, E. Mazzon, W. Fries

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Whereas medical approach to coeliac disease is well defined, treatment of patients who fail to respond to a gluten-free diet remains still problematic. We describe the case of a 68 years DQ-2 positive male who lost response to a strict gluten-free diet after an initial response over a 3-year period. His conditions became critical despite high dose prednisone treatment. After a careful differential diagnosis, the patient was classified as having a type I refractory coeliac disease and a single infusion of infliximab at 5 mg/kg was given with excellent clinical results. However, clinical response was lost despite background therapy with azathioprine. Six months after the single infusion an induction therapy with infliximab and, thereafter, maintenance every 8 weeks was administered with excellent clinical results. Since small bowel histology recovered very slowly treatment was continued over the following 2 years with a return to near normal architecture. This case shows that anti-tumour necrosis factor treatment may be used in carefully selected patients with type I refractory coeliac disease.

Original languageEnglish
Pages (from-to)74-77
Number of pages4
JournalDigestive and Liver Disease
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Celiac Disease
Gluten-Free Diet
Therapeutics
Azathioprine
Prednisone
Infliximab
Histology
Differential Diagnosis
Tumor Necrosis Factor-alpha
Maintenance

Keywords

  • Infliximab
  • Refractory coeliac disease
  • Therapy
  • TNF-α

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. / Costantino, G.; della Torre, A.; Lo Presti, M. A.; Caruso, R.; Mazzon, E.; Fries, W.

In: Digestive and Liver Disease, Vol. 40, No. 1, 01.2008, p. 74-77.

Research output: Contribution to journalArticle

Costantino, G. ; della Torre, A. ; Lo Presti, M. A. ; Caruso, R. ; Mazzon, E. ; Fries, W. / Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. In: Digestive and Liver Disease. 2008 ; Vol. 40, No. 1. pp. 74-77.
@article{86d314e5e59d44239c9ebb9caa129049,
title = "Treatment of life-threatening type I refractory coeliac disease with long-term infliximab",
abstract = "Whereas medical approach to coeliac disease is well defined, treatment of patients who fail to respond to a gluten-free diet remains still problematic. We describe the case of a 68 years DQ-2 positive male who lost response to a strict gluten-free diet after an initial response over a 3-year period. His conditions became critical despite high dose prednisone treatment. After a careful differential diagnosis, the patient was classified as having a type I refractory coeliac disease and a single infusion of infliximab at 5 mg/kg was given with excellent clinical results. However, clinical response was lost despite background therapy with azathioprine. Six months after the single infusion an induction therapy with infliximab and, thereafter, maintenance every 8 weeks was administered with excellent clinical results. Since small bowel histology recovered very slowly treatment was continued over the following 2 years with a return to near normal architecture. This case shows that anti-tumour necrosis factor treatment may be used in carefully selected patients with type I refractory coeliac disease.",
keywords = "Infliximab, Refractory coeliac disease, Therapy, TNF-α",
author = "G. Costantino and {della Torre}, A. and {Lo Presti}, {M. A.} and R. Caruso and E. Mazzon and W. Fries",
year = "2008",
month = "1",
doi = "10.1016/j.dld.2006.10.017",
language = "English",
volume = "40",
pages = "74--77",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - Treatment of life-threatening type I refractory coeliac disease with long-term infliximab

AU - Costantino, G.

AU - della Torre, A.

AU - Lo Presti, M. A.

AU - Caruso, R.

AU - Mazzon, E.

AU - Fries, W.

PY - 2008/1

Y1 - 2008/1

N2 - Whereas medical approach to coeliac disease is well defined, treatment of patients who fail to respond to a gluten-free diet remains still problematic. We describe the case of a 68 years DQ-2 positive male who lost response to a strict gluten-free diet after an initial response over a 3-year period. His conditions became critical despite high dose prednisone treatment. After a careful differential diagnosis, the patient was classified as having a type I refractory coeliac disease and a single infusion of infliximab at 5 mg/kg was given with excellent clinical results. However, clinical response was lost despite background therapy with azathioprine. Six months after the single infusion an induction therapy with infliximab and, thereafter, maintenance every 8 weeks was administered with excellent clinical results. Since small bowel histology recovered very slowly treatment was continued over the following 2 years with a return to near normal architecture. This case shows that anti-tumour necrosis factor treatment may be used in carefully selected patients with type I refractory coeliac disease.

AB - Whereas medical approach to coeliac disease is well defined, treatment of patients who fail to respond to a gluten-free diet remains still problematic. We describe the case of a 68 years DQ-2 positive male who lost response to a strict gluten-free diet after an initial response over a 3-year period. His conditions became critical despite high dose prednisone treatment. After a careful differential diagnosis, the patient was classified as having a type I refractory coeliac disease and a single infusion of infliximab at 5 mg/kg was given with excellent clinical results. However, clinical response was lost despite background therapy with azathioprine. Six months after the single infusion an induction therapy with infliximab and, thereafter, maintenance every 8 weeks was administered with excellent clinical results. Since small bowel histology recovered very slowly treatment was continued over the following 2 years with a return to near normal architecture. This case shows that anti-tumour necrosis factor treatment may be used in carefully selected patients with type I refractory coeliac disease.

KW - Infliximab

KW - Refractory coeliac disease

KW - Therapy

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=37048999189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37048999189&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2006.10.017

DO - 10.1016/j.dld.2006.10.017

M3 - Article

VL - 40

SP - 74

EP - 77

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 1

ER -